An update from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.
Shanghai Junshi Biosciences Co., Ltd. has announced a board meeting scheduled for April 25, 2025, to review and approve the unaudited financial results for the first quarter ending March 31, 2025. This meeting is significant as it provides insights into the company’s financial health and operational performance, which can impact its market positioning and stakeholder confidence.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biosciences industry. The company focuses on developing innovative therapies and pharmaceuticals, aiming to address unmet medical needs.
YTD Price Performance: 13.13%
Average Trading Volume: 2,007,613
Technical Sentiment Signal: Sell
Current Market Cap: HK$25.46B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.